Dashboard
Manage Tickers

URGN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

d-boral-capital-maintains-buy-on-urogen-pharma-maintains-25-price-target
D. Boral Capital Maintains Buy on UroGen P...
10/03/2025 12:34:55

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.

urogen-publishes-comprehensive-review-of-zusduri-for-recurrent-lg-ir-nonmuscle-invasive-bladder-cancer-titled-review-of-ugn-102-a-reverse-thermal-gel-containing-mitomycin-for-the-treatment-of-recurrent-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer
UroGen Publishes Comprehensive Review Of Z...
10/02/2025 12:05:30

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company focused on developing and commercializing innovative solutions for urotheli...

piper-sandler-initiates-coverage-on-urogen-pharma-with-overweight-rating-announces-price-target-of-36
Piper Sandler Initiates Coverage On UroGen...
08/19/2025 12:04:24

Piper Sandler analyst Kelsey Goodwin initiates coverage on UroGen Pharma (NASDAQ:URGN) with a Overweight rating and announce...

hc-wainwright--co-maintains-buy-on-urogen-pharma-lowers-price-target-to-40
HC Wainwright & Co. Maintains Buy on UroGe...
08/11/2025 10:35:36

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and lowers the price tar...

d-boral-capital-maintains-buy-on-urogen-pharma-maintains-25-price-target
D. Boral Capital Maintains Buy on UroGen P...
08/07/2025 18:50:55

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.

urogen-pharma-q2-2025-eps-105-misses-078-estimate-sales-24215m-beat-23136m-estimate
UroGen Pharma Q2 2025 EPS $(1.05) Misses $...
08/07/2025 12:12:40

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

d-boral-capital-maintains-buy-on-urogen-pharma-maintains-25-price-target
D. Boral Capital Maintains Buy on UroGen P...
08/05/2025 12:56:06

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.

urogen-pharma-announces-24-month-dor-of-722-by-kaplan-meier-estimate-in-patients-who-achieved-cr-at-three-months-from-phase-3-envision-trial-of-zusduri-for-intravesical-solution
UroGen Pharma Announces 24-Month DOR Of 72...
08/05/2025 12:07:01

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response...

urogen-pharma-announces-publication-in-reviews-in-urology-of-results-from-phase-3b-study-evaluating-feasibility-of-administering-zusduri-for-intravesical-solution-in-home-setting
UroGen Pharma Announces Publication In Rev...
07/28/2025 12:08:29

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative treatments for uroth...

urogen-announces-publication-of-results-from-five-year-term-extension-study-of-phase-2-optima-ii-trial-evaluating-zusduri
UroGen Announces Publication Of Results Fr...
07/21/2025 12:04:34

hc-wainwright--co-reiterates-buy-on-urogen-pharma-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on UroG...
07/08/2025 11:31:49

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $50 price...

d-boral-capital-maintains-buy-on-urogen-pharma-maintains-25-price-target
D. Boral Capital Maintains Buy on UroGen P...
07/07/2025 14:59:30

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.

urogen-completes-enrollment-in-phase-3-utopia-clinical-trial-of-ugn-103
UroGen Completes Enrollment In Phase 3 UTO...
07/07/2025 12:05:51

sage-therapeutics-roku-echostar-and-other-big-stocks-moving-higher-on-monday
Sage Therapeutics, Roku, EchoStar And Othe...
06/16/2025 14:49:31

us-stocks-likely-to-rebound-after-sharp-decline-amid-israel-iran-conflict-sp-500-historically-moves-higher-after-wars-says-expert
US Stocks Likely To Rebound After Sharp De...
06/16/2025 10:09:25

U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were highe...

why-urogen-pharma-urgn-stock-is-skyrocketing-this-week
Why UroGen Pharma (URGN) Stock Is Skyrocke...
06/13/2025 18:42:35

UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial resul...

scotiabank-maintains-sector-outperform-on-urogen-pharma-raises-price-target-to-47
Scotiabank Maintains Sector Outperform on ...
06/13/2025 17:34:24

Scotiabank analyst George Farmer maintains UroGen Pharma (NASDAQ:URGN) with a Sector Outperform and raises the price target ...

fda-approves-urogens-zusduri-as-first-drug-for-recurrent-bladder-cancer
FDA Approves UroGen's Zusduri As First Dru...
06/13/2025 14:53:59

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained re...

guggenheim-maintains-buy-on-urogen-pharma-raises-price-target-to-30
Guggenheim Maintains Buy on UroGen Pharma,...
06/13/2025 14:19:59

Guggenheim analyst Kelsey Goodwin maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $15 to $30.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION